Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Wyeth Effexor Label Revised With Suicide-Related Adverse Events Precaution

Executive Summary

Revised labeling for Wyeth's Effexor contains a precaution on reports of hostility and suicide-related adverse events in pediatric clinical trials with the serotonin and norepinephrine reuptake inhibitor
Advertisement

Related Content

FDA Requests Antidepressant Labeling Add Suicidality Warning
FDA Requests Antidepressant Labeling Add Suicidality Warning
Antidepressant Labeling Should Reflect Negative Pediatric Studies
Antidepressant Labeling Should Reflect Negative Pediatric Studies
Forest Lexapro “Re-Launch” For Generalized Anxiety Set For Mid-January
Forest Lexapro “Re-Launch” For Generalized Anxiety Set For Mid-January
GSK Discussing Paxil Pediatric Suicide Link With FDA; Label Change In U.K.
GSK Discussing Paxil Pediatric Suicide Link With FDA; Label Change In U.K.
Advertisement
UsernamePublicRestriction

Register

PS042444

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel